MeiraGTx (Group)

https://www.meiragtx.com

MeiraGTx (NASDAQ:MGTX) is a vertically integrated, clinical stage gene therapy company with four ongoing clinical programs and a broad pipeline of preclinical and research programs. MeiraGTx has core capabilities in viral vector design and optimization and gene therapy manufacturing, as well as a potentially transformative gene regulation technology. Led by an experienced management team, MeiraGTx has taken a portfolio approach by licensing, acquiring and developing technologies that give depth across both product candidates and indications. MeiraGTx’s initial focus is on three distinct areas of unmet medical need: inherited retinal diseases, severe forms of xerostomia and neurodegenerative diseases. Though initially focusing on the eye, salivary gland and central nervous system, MeiraGTx intends to expand its focus in the future to develop additional gene therapy treatments for patients suffering from a range of serious diseases. *

	Start	2018-10-05 existent
	Industry	gene therapy
	Industry 2	riboswitch technology
	Person	Forbes, Alexandria (MeiraGTx 201810 CEO)
	Person 2	Breedis, Katherine (MeiraGTx 201810– CFO before Stifel Nicolaus + Pfizer + Eli Lilly + Schroder + Goldman Sachs + Citi)

	Region	London, Greater London
	Country	United Kingdom (GB)
	Street	92 Britannia Walk
	City	N1 7NQ London
		Address record changed: 2020-12-02

Basic data	Employees	D: 101 to 500 (2022-12-31)
	Currency	USD
	Annual sales	15,920,000 (license revenue, related party, consolidated (2022) 2022-12-31)
	Profit	-129,615,000 (2022-12-31)
	Cash	115,516,000 (2022-12-31)

		* Document for »About Section«:

		Record changed: 2024-06-07